Effects of transdermal nicotine delivery on cognitive outcomes: A meta-analysis.
attention
cognition
healthy
memory
nicotine patch
non-smoker
Journal
Acta neurologica Scandinavica
ISSN: 1600-0404
Titre abrégé: Acta Neurol Scand
Pays: Denmark
ID NLM: 0370336
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
received:
23
02
2021
accepted:
11
04
2021
pubmed:
27
4
2021
medline:
20
7
2021
entrez:
26
4
2021
Statut:
ppublish
Résumé
By the association of nicotinic acetylcholine receptors in the brain, nicotine in the therapeutic window lowers neuronal damage and raises protective factors. These data, however, are contradicted by other findings. Here, we assessed the effects of transdermal nicotine administration on cognitive functions in healthy non-smoker adults by systematic review and meta-analysis of clinical trials. We included reports of clinical trials comparing the effects of nicotine patches with placebo in healthy non-smoking adults. The main outcome was the impact of nicotine patches on overall cognitive function with a focus on attention and memory. Standard meta-analytic and statistical methods measured the effect of transdermal nicotine compared with placebo patches. We included 31 publications involving 978 subjects. Nicotine patches boosted cognitive function in healthy adults (0.233 SMD, 95%CI, 0.111-0.355, p < .001). Overall heterogeneity of the studies was found to be modest (ϰ The meta-analysis showed that transdermal nicotine had statistically significant positive effects on attention, and non-significant effects on memory, in healthy non-smoking adults. The results encourage further studies of the therapeutic potential of nicotine patches in disorders of cognition.
Substances chimiques
Nicotine
6M3C89ZY6R
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
179-191Subventions
Organisme : Tabriz University of Medical Sciences
ID : 61017
Informations de copyright
© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Majdi A, Kamari F, Vafaee MS, Sadigh-Eteghad S. Revisiting nicotine's role in the ageing brain and cognitive impairment. Rev Neurosci. 2017;28(7):767-781.
Newhouse P, Singh A, Potter A. Nicotine and nicotinic receptor involvement in neuropsychiatric disorders. Curr Top Med Chem. 2004;4(3):267-282.
Wong DF, Kuwabara H, Horti AG, et al. Brain PET Imaging of α7-nAChR with [18F]ASEM: reproducibility, occupancy, receptor density, and changes in schizophrenia. Int J Neuropsychopharmacol. 2018;21(7):656-667.
Koukouli F, Changeux J-P. Do nicotinic receptors modulate high-order cognitive processing? Trends Neurosci. 2020;43(8):550-564.
Majdi A, Sadigh-Eteghad S, Talebi M, et al. Nicotine modulates cognitive function in D-galactose-induced senescence in mice. Front Aging Neurosci. 2018;10:194.
Bajrektarevic D, Corsini S, Nistri A, Tortora M. Nicotine neuroprotection of brain neurons: the other side of nicotine addiction. Neurosci Nicotine. Elsevier. 2019;79-86.
Heishman SJ, Kleykamp BA, Singleton EG. Meta-analysis of the acute effects of nicotine and smoking on human performance. Psychopharmacology. 2010;210(4):453-469.
Majdi A, Kamari F, Sadigh-Eteghad S, Gjedde A. Molecular insights into memory-enhancing metabolites of nicotine in brain: a systematic review. Front neurosci. 2019;12:1002.
Herzig KE, Callaway E, Halliday R, Naylor H, Benowitz NL. Effects of cotinine on information processing in nonsmokers. Psychopharmacology. 1998;135(2):127-132.
Howe MN, Price IR. Effects of transdermal nicotine on learning, memory, verbal fluency, concentration, and general health in a healthy sample at risk for dementia. Int Psychogeriatr. 2001;13(4):465-475.
Froeliger B, Gilbert DG, McClernon FJ. Effects of nicotine on novelty detection and memory recognition performance: double-blind, placebo-controlled studies of smokers and nonsmokers. Psychopharmacology. 2009;205(4):625-633.
Newhouse P, Kellar K, Aisen P, et al. Nicotine treatment of mild cognitive impairment: a 6-month double-blind pilot clinical trial. Neurology. 2012;78(2):91-101.
Wilson AL, Langley LK, Monley J, et al. Nicotine patches in alzheimer's disease: pilot study on learning, memory, and safety. Pharmacol Biochem Behav. 1995;51(2-3):509-514.
White HK, Levin ED. Four-week nicotine skin patch treatment effects on cognitive performance in alzheimer's disease. Psychopharmacology. 1999;143(2):158-165.
Gandelman JA, Kang H, Antal A, et al. Transdermal nicotine for the treatment of mood and cognitive symptoms in nonsmokers with late-life depression. J Clin Psychiatry. 2018;79(5):18m12137.
Park S, Knopick C, McGurk S, Meltzer HY. Nicotine impairs spatial working memory while leaving spatial attention intact. Neuropsychopharmacology. 2000;22(2):200-209.
Vangkilde S, Bundesen C, Coull JT. Prompt but inefficient: nicotine differentially modulates discrete components of attention. Psychopharmacology. 2011;218(4):667-680.
Centers_for_Disease_Control_Prevention. How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease: A Report of the Surgeon General. US: US Government Printing Office; 2010.
Matta SG, Balfour DJ, Benowitz NL, et al. Guidelines on nicotine dose selection for in vivo research. Psychopharmacology. 2007;190(3):269-319.
Skjei KL, Markou A. Effects of repeated withdrawal episodes, nicotine dose, and duration of nicotine exposure on the severity and duration of nicotine withdrawal in rats. Psychopharmacology. 2003;168(3):280-292.
Bannon YB, Corish J, Corrigan OI, Devane JG, Kavanagh M, Mulligan S. Transdermal delivery of nicotine in normal human volunteers: a single dose and multiple dose study. Eur J Clin Pharmacol. 1989;37(3):285-290.
Higgins JP, Altman DG, Gotzsche PC, et al. The cochrane collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
Zhang H, Huntley J, Bhome R, et al. Effect of computerised cognitive training on cognitive outcomes in mild cognitive impairment: a systematic review and meta-analysis. BMJ Open. 2019;9(8):e027062.
Borenstein M, Hedges L, Higgins J, Rothstein H. Introduction to Meta Analysis (Statistics in Practice). In: Chichester: Wiley-Blackwell; 2009.
Grundey J, Amu R, Ambrus GG, Batsikadze G, Paulus W, Nitsche MA. Double dissociation of working memory and attentional processes in smokers and non-smokers with and without nicotine. Psychopharmacology. 2015;232(14):2491-2501.
Grundey J, Amu R, Batsikadze G, Paulus W, Nitsche MA. Diverging effects of nicotine on motor learning performance: improvement in deprived smokers and attenuation in non-smokers. Addict Behav. 2017;74:90-97.
Min S, Moon IW, Ko R, Shin H. Effects of transdermal nicotine on attention and memory in healthy elderly non-smokers. Psychopharmacology. 2001;159(1):83-88.
White HK, Levin ED. Chronic transdermal nicotine patch treatment effects on cognitive performance in age-associated memory impairment. Psychopharmacology. 2004;171(4):465-471.
Prendergast MA, Jackson WJ, Terry AV Jr, Decker MW, Arneric SP, Buccafusco JJ. Central nicotinic receptor agonists ABT-418, ABT-089, and (-)-nicotine reduce distractibility in adult monkeys. Psychopharmacology. 1998;136(1):50-58.
Hahn B, Shoaib M, Stolerman I. Nicotine-induced enhancement of attention in the five-choice serial reaction time task: the influence of task demands. Psychopharmacology. 2002;162(2):129-137.
Wachter NJ, Gilbert DG. Nicotine differentially modulates antisaccade eye-gaze away from emotional stimuli in nonsmokers stratified by pre-task baseline performance. Psychopharmacology. 2013;225(3):561-568.
Wignall ND, de Wit H. Effects of nicotine on attention and inhibitory control in healthy nonsmokers. Exp Clin Psychopharmacol. 2011;19(3):183.
Ashare RL, Baschnagel JS, Hawk LW Jr. Subjective effects of transdermal nicotine among nonsmokers. Exp Clin Psychopharmacol. 2010;18(2):167-174.
Holmes AD, Chenery HJ, Copland DA. Transdermal nicotine modulates strategy-based attentional semantic processing in non-smokers. Int J Neuropsychopharmacol. 2008;11(3):389-399.
Picciotto MR. Nicotine as a modulator of behavior: beyond the inverted U. Trends Pharmacol Sci. 2003;24(9):493-499.
Newhouse PA, Potter A, Singh A. Effects of nicotinic stimulation on cognitive performance. Curr Opin Pharmacol. 2004;4(1):36-46.
Singer S, Rossi S, Verzosa S, et al. Nicotine-induced changes in neurotransmitter levels in brain areas associated with cognitive function. Neurochem Res. 2004;29(9):1779-1792.
Laviolette SR, van der Kooy D. The motivational valence of nicotine in the rat ventral tegmental area is switched from rewarding to aversive following blockade of the alpha7-subunit-containing nicotinic acetylcholine receptor. Psychopharmacology. 2003;166(3):306-313.
Seth P, Cheeta S, Tucci S, File SE. Nicotinic-serotonergic interactions in brain and behaviour. Pharmacol Biochem Behav. 2002;71(4):795-805.
Prictor M, Hill S. Cochrane consumers and communication review group: leading the field on health communication evidence. J Evid Based Med. 2013;6(4):216-220.
Macleod MR, O'Collins T, Horky LL, Howells DW, Donnan GA. Systematic review and metaanalysis of the efficacy of FK506 in experimental stroke. J Cereb Blood Flow Metab. 2005;25(6):713-721.